Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lantern Pharma Inc.LTRN · Entity 7525 | Director | May 12, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lantern Pharma Inc.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, $0.001 par valueSEC Table I · non-derivative | Direct | 48,544 |
Reported balance
After 2026-05-12 transaction · row 1
1 source rowRow 1 · 2026-05-12 · Purchase · Acquired 48,544 · Balance 48,544 F1: The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026. |
| Common stock purchase warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2031-11-13 | Direct | 48,544 |
Reported balance
After 2026-05-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-12 · Purchase · Disposed 48,544 · Balance 48,544 F1: The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2026 Filed May 14, 2026 20:10 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | PurchaseCommon stock purchase warrant (Right to Buy) · Derivative | 48,544 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001493152-26-023083 · ownership.xml · derivative · entry 2 Schalop Lee Troy · CIK 0002072339 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,544 Underlying: Common Stock · 48,544 shares Expires 2031-11-13 F1 · shares: The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026. F1 · derivative.exercise_date: The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:10 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | PurchaseCommon stock, $0.001 par value | 48,544 | $2.06 | $100,000.64 |
DisclosureSEC source: 0001493152-26-023083 · ownership.xml · nonDerivative · entry 1 Schalop Lee Troy · CIK 0002072339 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,544 F1 · shares: The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:05 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 18,460 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001493152-26-002026 · ownership.xml · derivative · entry 2 Schalop Lee Troy · CIK 0002072339 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,460 Underlying: Common Stock · 18,460 shares Expires 2036-01-08 F2 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:05 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001493152-26-002026 · ownership.xml · derivative · entry 1 Schalop Lee Troy · CIK 0002072339 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-01-08 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026. Read SEC document |
| August 19, 2025 Filed Aug 20, 2025 22:25 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001641172-25-025000 · ownership.xml · derivative · entry 1 Schalop Lee Troy · CIK 0002072339 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-08-18 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Equity Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 36-month period commencing September 19, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.